Added to YB: 2026-09-21
Pitch date: 2026-09-16
PALI [neutral]
Palisade Bio, Inc.
-9.14%
current return
Author Info
No bio for this author
Company Info
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.
Market Cap
$277.1M
Pitch Price
$1.75
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.30
P/E
-7.89
EV/Sales
303.84
Sector
Biotechnology
Category
growth
Biotech Conferences Week 2 Day 3 Part 1 - Palisade Bio, Inc.
PALI (quick overview): Palisade Bio’s gut-activated, colon-targeted PDE4 inhibitor is scientifically credible but lacks blinded, placebo-controlled evidence supporting differentiation. Signals from two five-patient IBD cohorts are only mechanistic; the first genuine proof-of-value event is the 204-patient Phase 2 ulcerative-colitis trial comparing two doses with placebo. At $1.88, it is an early-stage target/partner candidate to monitor, with distant data, financing needs and a crowded market the main risks.
Read full article (2 min)